To evaluate the efficacy and safety of intravenous nicardipine for the treatment of severe hypertension in pregnancy. Articles were identified through electronic databases (Medline and Cochrane). No date or language restrictions were placed. Relevant citations were hand searched. The following search terms were used: pregnancy, severe hypertension and nicardipine. Patients included had chronic or gestational hypertension with or without marked proteinuria. Primary outcomes were reduction of systolic/diastolic and/or mean arterial pressure, time to target blood pressure, and severe maternal (hypotension, tachycardia) or severe fetal side effects (CTG abnormalities needing direct intervention). Five studies were found describing the use of nicardipine for treatment of severe hypertension in pregnancy. All studies were included in this review. One hundred forty-seven patients were treated. All patients had a significant reduction of both diastolic and systolic blood pressure. Treatment resulted in a 91% success rate in studies that defined success and 20% reduction of mean arterial blood pressure or systolic/diastolic blood pressure in 87%. Target blood pressure was reached within 23 minutes in 70% of the patients, 91% reached target blood pressure within 130 minutes. No severe maternal or fetal side effects were recorded. Nicardipine is a very effective therapy for treatment of severe hypertension in pregnancy and may be a better alternative to other available treatment options.
Gestational hypertension affects almost 10% of all pregnancies and worldwide approximately 50,000 women die from gestational hypertensive disorders each year. There is general agreement that maternal risks are decreased by antihypertensive treatment (1) . So far, there is no consensus on the first choice antihypertensive medication. The most commonly used drugs for acute treatment of severe hypertension in pregnancy are: (di)hydralazine, labetalol and ketanserin.
For many years (di)hydralazine has been used as a first choice therapy to treat severe hypertension in pregnancy (1, 2) . Side effects such as headache, nausea, and vomiting are common (up to 50%) and mimic symptoms of deteriorating preeclampsia. Results of a meta-analysis do not support the use of (di)hydralazine (compared to other antihypertensives) as first-line treatment because of more maternal and fetal side effects with no evidence of a better antihypertensive effect (3) .
Labetalol has been used extensively in pregnancy and has a more favorable side effect profile. However, specific concern has been raised about the risk of neonatal hypotension, bradycardia, and hypoglycemia due to ß-adrenergic blockade with the use of parenteral labetalol (4) (5) (6) . Also, there is wide interpatient variability in the dose of labetalol required to control blood pressure (7) .
Ketanserin is a frequently used drug available only in some countries (the Netherlands, South Africa). Its pharmacological profile appears to be tailored for treating hypertension due to endothelial cell dysfunction. However, its blood-pressure-lowering effect is not always sufficient in gestational hypertensive disorders. A Cochrane (8) review concluded that ketanserin results in more persistent hypertension as compared to (di)hydralazine. Furthermore, because of its long half-life (12-16 hours) ketanserin is not easy to dose. Finally, the use of ketanserin should be carefully monitored by electro-cardiogram because of the prolonging effect of ketanserin on the QT interval, which may eventually result in cardiac arrest (9) .
Calcium antagonists have often successfully been prescribed during pregnancy, both for tocolysis (10, 11) and to treat hypertension during pregnancy (12, 13) . In these studies no severe maternal, fetal, or neonatal side-effects were observed. Pulmonary edema was observed (14) using nifedipine for tocolysis but this was in patients with a compromised cardiovascular condition (e.g., twin pregnancy, chorioamnionitis, cardiac disease).
Due to an increased risk of cardiac side-effects, headaches, and hot flushes, use of the fast acting calcium channel blocker nifedipine is not favored. Another calcium channel blocker, nicardipine, has a smaller negative inotropic effect and evokes fewer reflex tachycardia because of its more selective effect on blood vessels than nifedipine (15) . Nicardipine is licensed for use in acute severe hypertension and for postoperative hypertension. For these indications it shows a potent and fast reduction of the blood pressure after intravenous administration. Nicardipine seems to be very promising and may be a better alternative for the treatment of hypertensive disorders in pregnancy. This review evaluates the efficacy and safety of intravenous nicardipine for treatment of severe hypertension in pregnancy.
After completing this CME activity, readers will be better able to evaluate the relative effectiveness of nicardipine for the treatment of severe hypertension in pregnancy. Compare the side effect profile of nicardipine to labetolol for the treatment of severe hypertension in pregnancy and calculate the appropriate dosing of nicardipine for the treatment of hypertension in pregnancy.
PHARMACOLOGICAL PROPERTIES (16)
Nicardipine is a dihydropyridine derivate with a strong inhibitor action on L-type Ca 2ϩ channels resulting in inhibition of Ca 2ϩ influx in cardiac and vascular smooth muscle cells. Nicardipine is a potent vasodilator and is 10,000 times more selective for vascular smooth muscle than cardiac muscle (17) . Administration of nicardipine significantly decreases systemic vascular resistance (afterload). Cardiac output and ejection fraction increased following administration of 40-mg nicardipine in hypertensive patients. Following an IV bolus the clinically important half-life is in the order of 2 to 5 minutes. However, following a long-term IV infusion (24-48 hours) the clinically important half-life is in the order of 1 to 2 hours. Compared to other antihypertensive agents used in pregnancy nicardipine has the shortest half-life ( Table 1 ). The effects on blood pressure are significantly correlated with nicardipine plasma concentration. Nicardipine is highly protein bound (Ͼ95%) in human plasma over a wide concentration range. The pharmacokinetics of intravenously administered nicardipine is linear over the dosage range of 0.5 to 20.0 mg/h. Transplacental passage of nicardipine seems to be low. Plasma concentrations of nicardipine in the fetal monkey (7-35 ng/mL) reached only 6% of the maternal values (175-865 ng/mL) (18) . In human studies, intravenous infusion of nicardipine achieved lower mean plasma levels in both the maternal and fetal circulations (54.6 and 
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Obstetrical and Gynecological Survey 4.18 ng/mL, respectively), but the 9% transplacental transfer of nicardipine is of the same order of magnitude (19) . The current recommended dosage for rapid blood pressure control in nonpregnant patients is 5 mg/h, increasing the infusion rate by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h (20) . A dosage schedule during pregnancy has been suggested by Hanff et al (21): a starting dosage of 3 mg/h, which is increased by 0.5 to 1 mg/h to a maximum of 10 mg/h until the target blood pressure is reached.
Drug Interaction
Cimetidine increases nicardipine plasma levels. Patients receiving these 2 drugs concomitantly should be carefully monitored. Nicardipine does not usually alter the plasma levels of digoxin, however, serum digoxin levels should be re-evaluated when concomitant therapy with nicardipine is initiated. Concomitant use of nicardipine and MgSO 4 is described only twice in literature; there were no adverse reactions (21, 22) .
TOLERABILITY
Efficacy and safety of nicardipine were assessed in 29,104 hypertensive nonpregnant patients (23) . Most adverse reactions were transient and were related to vasodilatation: peripheral edema 7%, flushing 7%, and headache 4%. In a double-blind randomized study (24) to evaluate the efficacy and safety of intravenous nicardipine for treatment of postoperative hypertension the following adverse effects were seen: hypotension (4.5%), tachycardia (2.7%), nausea/vomiting (2%), and headache (2%). In the placebo group the incidence of adverse events was 2%. One case report described sinus bradycardia (25) when intravenous nicardipine was used. The author, however, described 3 other possible causes for the event in this patient. Pulmonary edema was described using intravenous nicardipine for tocolysis (26, 27) . As with nifedipine this complication occurred only in patients with compromised cardiovascular condition. Severe adverse fetal effects including hypoxemia, hypercapnia, acidosis, and death were reported only in animal experiments. It has been suggested that these adverse fetal effects were due to an excessive fall of maternal blood pressure caused by the extremely high doses of nicardipine administered (18, 28, 29) . Contraindications to the use of nicardipine are hypersensibility to nicardipine, severe aortic stenosis, hypotension, and shock.
SOURCES
We performed a Medline and Cochrane search and reviewed all available articles describing the use of intravenous nicardipine for treatment of severe hypertension in pregnancy. No date or language restrictions were placed (date of last search was December 2009). The following search terms were used: pregnancy, severe hypertension, and nicardipine. Data were abstracted independently by the 2 authors (S.N.B., J.J.D.), and discrepancies were resolved by discussion.
STUDY SELECTION
Randomized and observational studies describing the use of nicardipine for acute treatment of severe hypertension during pregnancy (gestational age Ͼ20 weeks) were included. Case reports and review articles were excluded. Severe hypertension was defined in all studies as mean diastolic blood pressure at enrolment of Ͼ110 mm Hg, using Korotkoff V. Hypertension was either chronic or gestational with or without proteinuria. Some studies enrolled mixed populations of women with either chronic hypertension or gestational hypertension with or without proteinuria; we used the term mixed hypertension in such instances.
The primary outcomes were reduction of systolic/ diastolic and/or mean arterial pressure, time to target blood pressure, and severe maternal (hypotension, tachycardia) or severe fetal (CTG abnormalities needing direct intervention) side effects. Secondary outcomes were persistent severe hypertension, other maternal (nausea, headache, palpitations, flushing) or fetal (Doppler velocimetry changes, loss of variability, variable decelerations) side effects and neonatal effects (nicardipine concentrations in different compartments, dysmaturity, and Apgar scores Ͻ7 after 5 minutes). If possible, nicardipine was compared to any other anti-hypertensive therapy.
RESULTS
The electronic searches yielded 12 articles, including 5 studies describing the use of nicardipine for treatment of severe hypertension in pregnancy (19, 21, 22, 30, 31) . All studies were included in this review. Table 2 shows selected characteristics of the included studies. Four studies enrolled patients with chronic and gestational hypertension with or without marked proteinuria. One study included patients with preeclampsia with no mention whether hypertension was chronic (31) . All studies noted whether or not patients were treated with other antihypertensive medication before inclusion. Successful therapy was variably defined: 20% lowering of arterial blood pressure in comparison to baseline levels (22), 20% to 30% decrease of mean arterial blood pressure (31), time needed until diastolic blood remained consistently below 90 mm Hg (19) , or percentage of patients reaching target diastolic blood pressure (below 100 mm Hg or below 90 mm Hg in HELLP patients) (21) . One study used no definition of success (30) . Therapy failed if success was not achieved. Seki (30) did not use a definition of failure. Assessment of outcome was not blinded in any of the studies. Two studies provided exclusion criteria (22, 30) .
One hundred forty-seven patients with severe hypertension were initially treated with nicardipine intravenously (Table 3 ). All patients had a significant reduction of both systolic and diastolic blood pressure. Carbonne et al (19) showed a 20% reduction of diastolic blood pressure in all patients using 2, 4, or 6 mg/h. In the group of Seki (30), blood pressure decreased significantly. Aya et al (31) showed a 20% reduction of mean arterial pressure in all patients within 1 hour, and 70% of patients had a 20% reduction of systolic and diastolic blood pressure or mean arterial pressure within 1 hour. In the study by Hanff et al (21) and Aya et al (31) , all patients reached target blood pressure within 1 hour. Time to success was short (21, 22, 31) : 11, 18, and 23 minutes, respectively. One study reported a longer period to achieve successful treatment (19) : 72, 123, 130 minutes for dosages of 2, 4, and 6 mg/h, respectively. No failures were observed in the studies by Aya et al (31), Carbonne et al (19) , and Hanff et al (21) .
Adverse reactions were not common (Table 4) . Nausea, palpitations, headache, flushing, and tachycardia were reported. The latter did not require discontinuation of therapy. Reduction of the nicardipine dosage and the use of ß-blockers to reduce the tachy- 
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Obstetrical and Gynecological Survey cardia was described in 2 patients (31). Eight patients (5%) had a transient episode of hypotension (21) (diastolic blood pressure Ͻ70 mm Hg) and 5 of these patients needed dosage reduction or discontinuation of therapy leading to a rapid recovery of diastolic blood pressure in all patients without signs of fetal distress. Loss of fetal variability was rare: 1 of 50 patients in the study of Seki et al (30) (no need for intervention). Aya et al (31) described loss of variability and slight decelerations which were transient, and intervention was not required. Transient decelerations appeared twice (7%) in the study of Hanff et al (21) . No other fetal/neonatal complications were noted. Doppler velocimetry was performed in one study (19) . No changes in the vascular resistance of uterine, umbilical or fetal middle cerebral arteries were observed.
Carbonne et al (19) studied nicardipine concentrations in different maternal and fetal compartments, and showed there was a decreasing concentration from the maternal side to the fetal side. Furthermore, tissue concentrations appeared to be nearly undetectable in maternal and fetal tissues a few hours after oral ingestion, suggesting that nicardipine does not accumulate in the placenta, membranes, and umbilical cord.
Two studies described combination therapy of MgSO 4 and nicardipine (21, 22) without adverse reactions.
Nicardipine Versus Labetalol
Elatrous et al (22) studied the effects of intravenous treatment with nicardipine (30 patients) versus labetalol (30 patients) during the first hour of treatment. Both regimens significantly decreased systolic and diastolic blood pressure within the first 5 minutes of infusion. Overall the decrease in blood pressure was significantly greater with nicardipine for both systolic and diastolic blood pressure. Drug dosage was modified in very few instances in both study groups: 1.4 Ϯ 0.4 times versus 0.5 Ϯ 0.2 in the nicardipine and labetalol groups, respectively (P ϭ 0.05). No patients in either group experienced a hypotensive episode. A slight but significant increase in heart rate was seen with nicardipine in comparison to baseline (P Ͻ 0.01). This effect did not require discontinuation of the medication. Other maternal side effects included nausea (n ϭ 2, 1 in each group) and palpitations (n ϭ 3, all in the nicardipine group). Fetal tolerance was generally good except for 1 episode of slight and transient deceleration in a patient from the labetalol group.
DISCUSSION
A review of the available literature shows that intravenous use of nicardipine is an effective therapy for the treatment of severe hypertension in pregnancy. In all patients a significant reduction of both diastolic and systolic blood pressures could be obtained during the study period. Treatment resulted in a 91% success rate in studies that defined success and a 20% reduction of mean arterial blood pressure or systolic/diastolic blood pressure in 87% of the patients during the study period. Target blood pressure was reached within 23 minutes in 70% of the patients, 91% reached target blood pressure within 130 minutes. The overall percentage of patients reaching target blood pressure is probably higher because results of 9 patients (22) were not provided after the study period of 1 hour. Carbonne et al (19) showed a longer interval to successful treatment possibly due to a different definition of success. No failures were noted in studies that defined failure. This finding contrasts with data on other antihypertensives, showing persistent severe hypertension after treatment with nifedipine (12%), labetalol (14%), (di)hydralazine (17%), and ketanserin (18%) (3). The recommended starting dosage of nicardipine is 1 to 3 mg/h, increasing the infusion rate by 1 mg/h to a maximum of 10 mg/h until the target blood pressure is reached. Our data show that nicardipine is a very effective drug for treatment of severe hypertension during pregnancy.
Besides sufficient therapeutic results, a limited number of severe maternal side effects were re- ported. The incidence of these side effects was comparable to that in nonpregnant patients. Only seldom was a short hypotensive overshoot observed. All these events showed complete rapid recovery after dosage reduction and never lead to fetal compromise. From the literature it remains unclear whether nicardipine results in fewer hypotensive periods than the other treatment options nifedipine, labetalol, (di)hydralazine, and ketanserin. A meta-analysis (3) found more hypotensive events with hydralazine than labetalol (RR: 5.46; 95% CI: 1.14-26.23). Other combinations (3, 8) of antihypertensives showed nonsignificant differences. Three studies showed an increase in maternal heart rate (without need for discontinuation) presumably as a result of sympathetic stimulation from lowered blood pressure (21, 22, 31) . No pulmonary edema was described in the included studies. However care has to be taken when maternal cardiovascular condition is compromised. Mild adverse maternal reactions were less frequent with the use of nicardipine (22%) as compared to (di)hydralazine (53%-77%), labetalol (40%), or ketanserin (32%). Fetal complications were scarce. Few cases of transient loss of variability and variable decelerations were observed, but this was never severe enough to intervene. However, it has to be noted that the interpretation of the cardiotocography was not described in any of the studies. Other parameters for fetal condition were biophysical profile and the pulsatility index of the umbilical artery. No significant changes in these parameters were observed after institution of the therapy. The incidence of neonatal side effects such as growth restriction, prematurity, and cesarean delivery are compatible with data reported in the literature for other antihypertensive drugs (32) and for nifedipine (33) . The only long-term neonatal follow-up was given by Aya et al (31): 4 patients delivered within 1 hour after initiation of nicardipine therapy. These patients were already planned for cesarean section due to fetal distress or critical maternal condition. During an observation period of 1 to 7 weeks no neonatal side effects attributed to maternal use of nicardipine were observed. This is in agreement with the results of previous studies using calcium antagonists, in which adverse outcomes were due to complications of prematurity or to congenital abnormalities (12, (33) (34) (35) (36) .
Studies comparing nicardipine with other antihypertensives are scarce. One randomized controlled trial was included in this review (22) comparing nicardipine with labetalol. Nicardipine decreased systolic and diastolic blood pressure significantly better. No significant differences in maternal, fetal or neonatal side effects were found.
Pregnant patients treated for severe hypertension are at risk of developing eclamptic fits. MgSO 4 is the treatment of choice to prevent and treat this complication (37) . Often patients receive antihypertensive treatment in combination with MgSO 4 . The mechanism by which parenteral MgSO 4 prevents seizures is only partially understood. One possible action of MgSO 4 is an N-methyl-D-aspartate receptor inhibitory effect which inhibits Ca-influx (38) . Theoretically concomitant use of calcium antagonists may have a synergetic effect. Case reports describe neuromuscular blockade and hypotension when nifedipine and MgSO 4 were used in combination (39, 40) . No causal explanation was found. Two studies described combination therapy of MgSO 4 and nicardipine (21, 22) without adverse reactions. Nevertheless, concomitant use of MgSO 4 and nicardipine should be monitored carefully.
Our review has the following limitations. The total number of studies and study participants was limited, only 5 studies were available. Most of these studies were retrospective or observational. Only 1 prospective randomized trial could be included. The endpoints of the studies were not uniform. There were wide dosage differences. Despite these limitations we were able to perform subgroup analysis since much of the data could be compared and aggregated.
At present, the first-line medical treatment of severe hypertension in pregnancy remains unclear. Authors of a Cochrane systematic review concluded that ketanserin is probably not a good choice (8) . A large meta-analysis (3) did not support use of (di)hydralazine as first-line treatment of severe hypertension in pregnancy. Labetalol and nifedipine were deemed the most promising agents in this analysis.
Calcium antagonists (nifedipine) have proven to be effective for treatment of severe hypertension in pregnancy. Nicardipine seems to be preferable when compared to nifedipine because of its smaller negative inotropic effect, fewer reflex tachycardia, and less persistent severe hypertension. Based on the present study, nicardipine is a very effective therapy for treatment of severe hypertension in pregnancy and may be a better alternative than the other available treatment options. However, more studies are needed to provide safety aspects of this agent after which nicardipine could become a definite place in the treatment of severe hypertension in pregnancy.
After completing this CME activity, readers will be better able to evaluate the relative effectiveness of nicardipine for the treatment of severe hypertension
